Is Botox safe while breastfeeding?

The verdict

Wait. This is the one page in this batch where the answer is no, and it is worth being clear that it is a no built on absence of evidence rather than on evidence of harm.

Botulinum toxin is a prescription-only medicine. In the UK the MHRA licenses three brands for cosmetic use, and supplying an unlicensed product is an offence carrying up to two years in prison and unlimited fines under the Human Medicines Regulations 2012. It is not a cosmetic in the regulatory sense, and the safety questions attached to it are medicines questions.

Moorfields Eye Hospital, which gives botulinum toxin therapeutically for squint, states the position plainly: there is no published information about the medical use of botulinum toxin in breastfeeding. Its own advice is that no medication, unless it is absolutely necessary, should be given during pregnancy or breastfeeding. A wrinkle is not absolutely necessary, and it will still be there in six months.

What is and is not known

The honest evidence picture is short.

Moorfields reports one published case of a woman with botulism, a naturally occurring and far more severe exposure than any injection, who safely breastfed her infant, and no botulinum toxin was found in her milk. Against that, it notes that botulinum toxin has been found in the breast milk of animals with botulism. In experimental studies in rabbits, daily injections led to maternal toxicity, miscarriage and foetal abnormalities.

The mechanistic argument for safety is straightforward and is the one most practitioners give: the toxin is injected into a specific muscle, acts locally at the neuromuscular junction, and is a very large protein that would not be expected to cross into milk in meaningful amounts. That argument is plausible. It is also untested in lactating humans, which is exactly what Moorfields says.

Its conclusion is the appropriate one for elective use: although the current limited evidence available would suggest there have been no harmful effects in humans, safety cannot be completely guaranteed.

The risk that is actually documented

The strongest reason to defer cosmetic injectables right now has nothing to do with milk. It is the product supply chain.

Between 4 June and 6 August 2025, 41 confirmed cases of botulism were reported across several regions of England, linked to suspected use of unlicensed botulinum toxin products in cosmetic procedures. The MHRA's Criminal Enforcement Unit found that some sellers and practitioners, often untrained, were obtaining unlicensed products illegally and injecting them in informal settings including domestic bedrooms and kitchens, hair salons and mobile beauty services, with customers drawn in by social media adverts promising quick, cheap results.

Botulism causes paralysis and is potentially life-threatening. A mother who cannot safely hold or feed her baby is a far more concrete problem than any theoretical transfer into milk.

The regulatory picture is still being built. It is already a criminal offence in England to administer injectable toxins or fillers for a cosmetic purpose to anyone under 18, under the Botulinum Toxin and Cosmetic Fillers (Children) Act 2021. The government has consulted on a licensing scheme under which practitioners would need to be licensed for specific procedures and their premises licensed too, with the highest-risk procedures becoming Care Quality Commission regulated activities. Until that is in force, the sector is largely unregulated at the practitioner level.

What about fillers, peels and laser

The same reasoning applies with the same force, for the same reason: they are elective, the lactation evidence is absent, and the procedures carry their own infection and injury risks that are not worth accepting on a timetable you control.

Dermal fillers are the other product covered by the under-18 ban and the proposed licensing scheme, and the consultation groups them with botulinum toxin as procedures needing stricter oversight. Chemical peels and laser treatments are also in scope of the government's risk-based classification work.

There are two practical exceptions worth naming. Anything prescribed for a medical rather than cosmetic reason is a conversation with your prescriber, not a decision to make from a webpage, and that includes botulinum toxin given for migraine, spasticity, hyperhidrosis or squint. And ordinary topical skincare, facials, waxing, threading and massage are not in this category at all.

If you have already had it

Do not stop breastfeeding on the strength of it. The CDC's list of contraindications to breastfeeding does not include cosmetic injectables, and the single relevant human report found no toxin in milk.

What matters is whether the product was licensed and who injected it. If you had treatment somewhere informal, from someone whose qualifications you cannot verify, or with a product you cannot identify, watch for the symptoms of botulism, which include drooping eyelids, blurred or double vision, slurred speech, difficulty swallowing and muscle weakness spreading from the face downwards. These can appear days after treatment. Seek urgent medical help if any of them develop, and say what you had and when.

If you had treatment at a reputable clinic with a licensed product and feel well, there is nothing to monitor. Moorfields' own practice for therapeutic injections is to advise expressing milk to use for 24 to 48 hours afterwards, which gives a sense of the caution clinicians apply, but that is guidance attached to a clinical indication and a clinical consent process, not to a cosmetic appointment.

Where guidance differs

There is no disagreement, because there is almost no guidance. No national health authority in the UK, Ireland or the US publishes a position on cosmetic botulinum toxin while breastfeeding, in either direction.

What exists is regulatory rather than clinical. The MHRA regulates the products and prosecutes illegal supply. The Department of Health and Social Care is legislating on who may perform the procedures and where. The CDC lists what genuinely contraindicates breastfeeding, and cosmetic procedures are not on it. The NHS no longer maintains a consumer page on botulinum toxin injections at all, having consolidated its cosmetic procedures content into general advice about choosing a practitioner.

Absence of guidance is not permission. For an elective procedure with no lactation data, a prescription-only product and a documented recent cluster of botulism cases from illegal supply, the sensible reading of that silence is to wait.